Read More

Castle Biosciences Announces Results From A Randomized Controlled Trial Show That TissueCypher Barrett’s Esophagus Test Results Can Significantly Improve The Accuracy Of Risk Assessments And Adherence To Guideline-recommended Patient Management

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a randomized controlled trial (RCT) showing that use of TissueCypher®

CSTL

Read More

Reported Early Thursday, ObsEva Announces IND Approval For Yuyuan Bioscience’s Phase 1 Clinical Trial Of Nolasiban To Improve Clinical Pregnancy And Live Birth Rates In Women Undergoing In Vitro Fertilization In China

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 13, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))), a biopharmaceutical company developing novel

OBSV